JPMorgan Indian Investment Trust plc
JPIVF
Other OTC- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Rukhshad Tehmton Shroff
- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 60 Victoria Embankment London United Kingdom EC4Y 0JP
- IPO Date
- Oct 15, 2010
- Website
- am.jpmorgan.co.uk
- Similar Companies
- Business
- JPMorgan Indian Investment Trust plc (JPMorgan Indian Investment Trust plc) is a United Kingdom-listed closed-end investment trust that seeks long-term capital growth through investment in a diversified portfolio of equity and equity-related securities of Indian companies. The trust provides investors with exposure to the Indian equity market, primarily through direct investments in listed and unlisted securities; it employs a bottom-up stock selection process focusing on high-quality companies with strong growth prospects across sectors such as financials, information technology, consumer goods, healthcare, and industrials. Managed by JPMorgan Asset Management (UK) Limited, the trust offers ordinary shares traded on the London Stock Exchange under the ticker JII (OTC: JPIVF), with a market capitalization reflecting its focus on mid- and large-cap Indian equities; it also provides gearing through borrowing to enhance returns. Founded in 1994 and headquartered in London, England, the trust targets institutional and retail investors seeking dedicated exposure to India's fast-growing economy, operating exclusively within the Indian subcontinent with no significant international diversification. Its portfolio typically comprises 40-60 holdings, emphasizing companies benefiting from India's demographic trends, urbanization, and rising consumer spending; key holdings often include established names in banking, technology services, and pharmaceuticals. The trust maintains a policy of distributing income through dividends, supplemented by revenue reserves, while prioritizing capital appreciation. In recent developments, the trust announced a proposed combination with JPMorgan Asia Growth & Income plc in September 2024, aiming to create a larger Asia ex-Japan focused investment trust with enhanced scale and reduced costs; this strategic merger, subject to shareholder approval expected in early 2025, represents a significant reorganization to broaden geographic scope beyond India while retaining substantial Indian exposure. Additionally, in 2024, the trust launched a tender offer to repurchase up to 10% of its shares, supporting shareholder liquidity amid market volatility; it also adjusted its investment policy to allow greater flexibility in unlisted investments up to 10% of gross assets, reflecting adaptation to evolving Indian market opportunities. These changes underscore the trust's proactive management amid India's robust economic expansion and global investor interest in emerging markets.